RecruitingNCT05775458

Glutamate Excitotoxicity and Its Role in Glioblastoma Biology

Role of Glutamate-mediate Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme

Sponsor

IRCCS San Raffaele

Enrollment

50 participants

Start Date

Jun 1, 2020

Study Type

OBSERVATIONAL

Conditions

Brain Tumor, Primary

Summary

Gliomas are the most frequent type of primary brain tumors in adults; among them glioblastoma multiforme (GBM) is the most malignant, being associated with the worst prognosis. Glutamate (Glu) is an aminoacid, responsible for essential functions in the Central Nervous System (CNS), acting both as metabolite and neurotransmitter. It is essential for regulating cellular metabolism and developmental synaptogenesis, cellular migration, differentiation and death. Recent scientific evidences have demonstrated alteration in Glu synthesis and signaling being directly involved in GBM growth and invasion

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating the role of glutamate — a chemical in the brain — in glioblastoma (GBM), the most aggressive type of brain tumor. Researchers believe that glioblastoma cells use excess glutamate to promote tumor growth (a process called excitotoxicity), and they want to understand this mechanism better by studying samples taken during surgery. **You may be eligible if...** - You are an adult (18 or older) with a brain lesion suspected to be glioblastoma - You are scheduled for surgery to remove as much of the tumor as possible - You will be treated with standard radiation and chemotherapy afterward - You are able to give informed consent **You may NOT be eligible if...** - You are under 18 - You have liver disease - You have severe anemia - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.